Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo

Fig. 3

Monospecific antibody targeting of CHD11 reduced the CD44hiCD24neg/lo population and suppressed the metastatic potential of breast cancer cells. a Photo-images (upper panel) and histograms (lower panel) show the effect of anti-CDH11 antibody treatment on the motility of MCF7 and MDA-MB-231 as demonstrated by scratch-wound healing assay. b Photo-images with densitometry quantification from western blot analyses show the effect of anti-CDH11 antibody treatment on the expression of vimentin, fibronectin, β-catenin, and E-cadherin proteins in MCF7 and MDA-MB-231 cells. c Photo-images (upper panel) and histograms (lower panel) show the effect of anti-CDH11 antibody on the quality and quantity of mammospheres formed. d Representative flow cytometry dot-plot of CD24-PE vs. CD44-FITC showing the effect of exposure to anti-CDH11 antibody on the CD44hi/CD24neg/lo breast CSC population among the MCF7 and MDA-MB-231 cells. FITC, fluorescein isothiocyanate; PE, phycoerytherin; isotype control, FITC or PE conjugated IgG; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001

Back to article page